It is currently Sun May 29, 2016 8:34 am
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
Objective: We are conducting an open-label phase 1b study on the efficacy of intrathecal (IT) administration of rituximab, provided via an Ommaya reservoir, for the treatment of progressive multiple sclerosis (PMS). The objective of this initial study was to monitor B lymphocytes in peripheral blood (PB) and CSF from the first 10 patients 1 year ...
Total posts 232494 • Total topics 24863 • Total members 16018